How many 8-K filings has Neurocrine Biosciences Inc filed?

Neurocrine Biosciences Inc (NBIX) has 14 8-K (Current Event Report) filings on record, spanning Feb 2024 to Apr 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Neurocrine Biosciences Inc 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Neurocrine Biosciences Inc 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Neurocrine Biosciences Inc (NBIX) — 8-K Filings

All 8-K filings from Neurocrine Biosciences Inc. Browse 14 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (14)

8-K Filing — Apr 6, 2026
8-K Filing — Nov 24, 2025
Neurocrine Biosciences Files 8-K on Officer/Director Changes — May 30, 2025 Risk: low
Neurocrine Biosciences, Inc. filed an 8-K on May 30, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of ce
Neurocrine Biosciences Announces Executive and Board Changes — May 22, 2025 Risk: medium
Neurocrine Biosciences, Inc. announced on May 21, 2025, several key executive and board changes. These include the departure of Director Dr. Richard H. Scheller
Neurocrine Biosciences Adds New Director — Apr 4, 2025 Risk: low
Neurocrine Biosciences, Inc. announced on April 2, 2025, the election of Dr. David L. M. M.D. to its Board of Directors. Dr. M.D. will serve as a Class II direc
Neurocrine Biosciences Files 8-K on Financials — Feb 6, 2025 Risk: low
Neurocrine Biosciences, Inc. filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
Neurocrine Biosciences Enters Material Definitive Agreement — Jan 27, 2025 Risk: medium
Neurocrine Biosciences, Inc. (NBIX) announced on January 24, 2025, the entry into a material definitive agreement. The filing also includes information regardin
Neurocrine Biosciences Files 8-K — Dec 20, 2024 Risk: low
Neurocrine Biosciences, Inc. filed an 8-K on December 20, 2024, to report other events. The filing does not contain specific details about the nature of these e
Neurocrine Biosciences Files 8-K — Nov 1, 2024 Risk: low
Neurocrine Biosciences, Inc. filed an 8-K on November 1, 2024, reporting an event on October 31, 2024. The filing is categorized under 'Other Events' and does n
Neurocrine Biosciences Announces Executive and Director Changes — Oct 11, 2024 Risk: medium
Neurocrine Biosciences, Inc. announced on October 11, 2024, changes in its executive and director roles. Specifically, the company reported the departure of cer
Neurocrine Biosciences Files 8-K — Aug 28, 2024 Risk: medium
Neurocrine Biosciences, Inc. filed an 8-K on August 28, 2024, to report an Other Event and Regulation FD Disclosure. The filing does not contain specific financ
Neurocrine Biosciences Elects New Directors, Amends Bylaws — May 28, 2024 Risk: low
Neurocrine Biosciences, Inc. announced on May 24, 2024, a change in its board of directors, with the election of two new directors, Dr. Richard A. F. Clark and
Neurocrine Biosciences Adds Dr. P. Brandon Davis to Board — May 23, 2024 Risk: low
Neurocrine Biosciences, Inc. announced on May 22, 2024, the election of Dr. P. Brandon Davis to its Board of Directors, effective immediately. Dr. Davis, a seas
Neurocrine Biosciences Files 8-K on Financial Results — Feb 7, 2024
Neurocrine Biosciences, Inc. filed an 8-K on February 7, 2024, to report its results of operations and financial condition. This filing, under Items 2.02 and 9.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX